Breast Cancer Study Reveals Lung Metastases' Unique Behavior
A groundbreaking study, published in Science Advances, has shed light on the distinct behaviors of metastatic triple-negative breast cancer cells in the lungs and liver. Led by Dr. Angela Riedel and her team at the Mildred-Scheel Early Career Center (MSNZ) at the University Hospital Würzburg (UKW), the research reveals that certain genes in the TNF-α pathway may contribute to the success of lung metastases.
The study, which analysed 31 triple-negative breast cancer subclones in mice and human samples using a novel optical barcoding strategy, found that lung metastases exhibit a greater diversity of cancer cells compared to those in the liver. Furthermore, the inflammatory tumor necrosis factor alpha (TNF-α) pathway was notably upregulated in lung metastases, setting them apart from their liver counterparts. This pathway, when activated, can promote the growth and spread of cancer cells, potentially explaining the increased success of lung metastases.
The team's findings also identified a specific set of genes that can differentiate between lung and liver metastases. This discovery could pave the way for more targeted and effective treatments for metastatic breast cancer, tailored to the specific organ affected.
The study, published in Science Advances, highlights the unique characteristics of lung and liver metastases from triple-negative breast cancer. By identifying the key role of the TNF-α pathway and specific genes in lung metastases, the research opens avenues for more personalized and effective treatments, ultimately improving patient outcomes.
